Combination of | |
---|---|
Secobarbital | Short-acting barbiturate |
Amobarbital | Intermediate-acting barbiturate |
Clinical data | |
Trade names | Tuinal |
Routes of administration | By mouth |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
PubChem CID | |
Chemical and physical data | |
3D model (JSmol) | |
| |
|
Tuinal was the brand name of a discontinued combination drug composed of two barbiturate sodium salts (secobarbital and amobarbital) in equal proportions.
Tuinal was introduced as a sedative-hypnotic (sleeping pill) medication in the late 1940s by Eli Lilly. It was also used in obstetrics for childbirth.[1][2] It was produced in brightly colored half-reddish orange and half-turquoise blue gelatin capsule form (bullet-shaped Pulvules) for oral administration. Individual capsules contained 50 mg, 100 mg, or 200 mg of barbiturate salts. The combination of a short-acting barbiturate, secobarbital, with an intermediate-acting barbiturate, amobarbital, aimed to provide "a rapid yet prolonged hypnotic action".[3]
Eli Lilly has discontinued the manufacture of Tuinal in the United States due to the diminishing use of barbiturates (largely replaced by the benzodiazepine family of drugs) in outpatient treatment, and its widespread abuse.[4] Currently, Valleant Labs markets secobarbital capsules only. Flynn Pharma of Ireland no longer manufactures Tuinal, Seconal (secobarbital), or Amytal (amobarbital). Amytal has been discontinued, though injectable forms of amobarbital sodium remains.